查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1857133

人工血液替代品：全球市佔率排名、總銷售額和需求預測（2025-2031年）

Artificial Blood Substitute - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 83 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球人工血液替代品市場規模預計在 2024 年達到 1,056 萬美元，預計到 2031 年將達到 4,814 萬美元，在 2025-2031 年預測期內的複合年成長率為 25.4%。

人造血液是指人造血球及其功能替代品。顧名思義，人造血液的功能是取代真正的人體血液，以滿足人們的血液需求，並彌補當前血液短缺的狀況。

人工血液替代品市場的主要驅動力是不斷成長的醫療需求和技術進步。儘管全球輸血需求持續成長，但充足的血液供應往往受到血型相容性、保存期限有限以及血液供應系統不完善等挑戰的限制。人工血液替代品在急救、大規模傷亡事件和戰場醫療中發揮著至關重要的作用。此外，人口老化加劇以及重大手術和創傷病例的增加，也使得臨床對安全、持久且通用的替代品產生了強烈的需求。生物工程、奈米技術和合成生物學的進步也推動了更有效率、更穩定的產品的研發。此外，對輸血相關感染疾病的擔憂以及某些地區較低的捐血率，也促使醫療機構優先考慮人工血液解決方案，這些因素共同推動了市場成長。

本報告旨在全面概述全球人工血液替代品市場，重點關注總銷售收入、市場佔有率和主要企業的排名，並按地區/國家、類型和應用進行分析。

人工血液替代品市場規模、估算和預測均以銷售收入（百萬美元）為基礎，以2024年為基準年，提供2020年至2031年的歷史數據和預測數據。定量和定性分析有助於讀者制定業務/成長策略、評估競爭格局、分析公司在當前市場中的地位，並就人工血液替代做出明智的商業決策。

目錄

第1章 市場概覽

  • 人工血液代用品介紹
  • 全球人工血液替代品市場規模預測（2020-2031年）
  • 人工血液替代品市場趨勢及促進因素
  • 前提條件和限制條件
  • 調查目的
  • 多年的考慮

第2章 公司競爭分析

  • 全球人工血液替代品公司收入排名（2024 年）
  • 全球人工血液替代品公司收入（2020-2025 年）
  • 主要人工血液替代品製造地及總部分佈
  • 提供主要製造商的人工血液替代品
  • 大型生產商何時開始大規模生產人造血液替代品？
  • 人工血液替代品市場競爭分析
  • 併購、擴張

第3章 依類型細分

  • 按類型介紹
    • 全氟碳氧載體（PFBOC）
    • 基於血紅素的氧載體（HBOCs）
  • 全球人造血液替代品銷售額（按類型分類）

第4章 按應用程式分類的章節

  • 透過申請
    • 軍隊
    • 私人的
  • 全球人工血液替代品銷售額（按應用領域分類）

第5章：區域細分

  • 全球各地區人造血液替代品銷售額
  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第6章 按主要國家分類

  • 主要國家和地區人工血液替代品銷售額成長趨勢（2020 年、2024 年和 2031 年比較）
  • 2020-2031年主要國家及地區人造血液替代品銷售額
  • 美國
  • 歐洲
  • 中國
  • 日本
  • 韓國
  • 東南亞
  • 印度

第7章 公司簡介

  • Aurum Biosciences Ltd.
  • Hemarina
  • HbO2 Therapeutics
  • KaloCyte Inc.
  • SpheriTech Ltd.
  • NuvOx Pharma
  • Safi Biotherapeutics

第8章：產業鏈分析

第9章 研究結果與結論

第10章附錄

The global market for Artificial Blood Substitute was estimated to be worth US$ 10.56 million in 2024 and is forecast to a readjusted size of US$ 48.14 million by 2031 with a CAGR of 25.4% during the forecast period 2025-2031.

Artificial blood refers to artificial blood cells and their functional substitutes. Its function, as the name suggests, is to replace real human blood to meet people's demand for blood and make up for the current blood shortage.

The market for artificial blood substitutes is primarily driven by increasing medical demand and advancements in technology. On a global scale, the demand for blood transfusions continues to rise, while the availability of suitable blood is often constrained by challenges such as blood type compatibility, limited shelf life, and underdeveloped blood supply systems. Artificial blood substitutes can play a vital role in emergency care, mass casualty incidents, and battlefield medicine. In addition, the accelerating aging population, along with the growing number of major surgeries and trauma cases, has created strong clinical demand for safe, long-lasting, and universally compatible alternatives. Advances in bioengineering, nanotechnology, and synthetic biology are also fostering the development of more efficient and stable products. Furthermore, concerns over transfusion-related infections and low blood donation rates in certain regions are encouraging healthcare systems to prioritize artificial blood solutions, collectively driving market growth.

This report aims to provide a comprehensive presentation of the global market for Artificial Blood Substitute, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Artificial Blood Substitute by region & country, by Type, and by Application.

The Artificial Blood Substitute market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Artificial Blood Substitute.

Market Segmentation

By Company

  • Aurum Biosciences Ltd.
  • Hemarina
  • HbO2 Therapeutics
  • KaloCyte Inc.
  • SpheriTech Ltd.
  • NuvOx Pharma
  • Safi Biotherapeutics

Segment by Type

  • Perfluorocarbon-based Oxygen Carrier (PFBOC)
  • Hemoglobin-based Oxygen Carrier (HBOC)

Segment by Application

  • Military
  • Civil

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Artificial Blood Substitute company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Artificial Blood Substitute in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Artificial Blood Substitute in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Artificial Blood Substitute Product Introduction
  • 1.2 Global Artificial Blood Substitute Market Size Forecast (2020-2031)
  • 1.3 Artificial Blood Substitute Market Trends & Drivers
    • 1.3.1 Artificial Blood Substitute Industry Trends
    • 1.3.2 Artificial Blood Substitute Market Drivers & Opportunity
    • 1.3.3 Artificial Blood Substitute Market Challenges
    • 1.3.4 Artificial Blood Substitute Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Artificial Blood Substitute Players Revenue Ranking (2024)
  • 2.2 Global Artificial Blood Substitute Revenue by Company (2020-2025)
  • 2.3 Key Companies Artificial Blood Substitute Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Artificial Blood Substitute Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Artificial Blood Substitute
  • 2.6 Artificial Blood Substitute Market Competitive Analysis
    • 2.6.1 Artificial Blood Substitute Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Artificial Blood Substitute Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Artificial Blood Substitute as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
    • 3.1.2 Hemoglobin-based Oxygen Carrier (HBOC)
  • 3.2 Global Artificial Blood Substitute Sales Value by Type
    • 3.2.1 Global Artificial Blood Substitute Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Artificial Blood Substitute Sales Value, by Type (2020-2031)
    • 3.2.3 Global Artificial Blood Substitute Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Military
    • 4.1.2 Civil
  • 4.2 Global Artificial Blood Substitute Sales Value by Application
    • 4.2.1 Global Artificial Blood Substitute Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Artificial Blood Substitute Sales Value, by Application (2020-2031)
    • 4.2.3 Global Artificial Blood Substitute Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Artificial Blood Substitute Sales Value by Region
    • 5.1.1 Global Artificial Blood Substitute Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Artificial Blood Substitute Sales Value by Region (2020-2025)
    • 5.1.3 Global Artificial Blood Substitute Sales Value by Region (2026-2031)
    • 5.1.4 Global Artificial Blood Substitute Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Artificial Blood Substitute Sales Value, 2020-2031
    • 5.2.2 North America Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Artificial Blood Substitute Sales Value, 2020-2031
    • 5.3.2 Europe Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Artificial Blood Substitute Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Artificial Blood Substitute Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Artificial Blood Substitute Sales Value, 2020-2031
    • 5.5.2 South America Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Artificial Blood Substitute Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Artificial Blood Substitute Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Artificial Blood Substitute Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Artificial Blood Substitute Sales Value, 2020-2031
    • 6.3.2 United States Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Artificial Blood Substitute Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Artificial Blood Substitute Sales Value, 2020-2031
    • 6.4.2 Europe Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Artificial Blood Substitute Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Artificial Blood Substitute Sales Value, 2020-2031
    • 6.5.2 China Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Artificial Blood Substitute Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Artificial Blood Substitute Sales Value, 2020-2031
    • 6.6.2 Japan Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Artificial Blood Substitute Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Artificial Blood Substitute Sales Value, 2020-2031
    • 6.7.2 South Korea Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Artificial Blood Substitute Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Artificial Blood Substitute Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Artificial Blood Substitute Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Artificial Blood Substitute Sales Value, 2020-2031
    • 6.9.2 India Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Artificial Blood Substitute Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Aurum Biosciences Ltd.
    • 7.1.1 Aurum Biosciences Ltd. Profile
    • 7.1.2 Aurum Biosciences Ltd. Main Business
    • 7.1.3 Aurum Biosciences Ltd. Artificial Blood Substitute Products, Services and Solutions
    • 7.1.4 Aurum Biosciences Ltd. Artificial Blood Substitute Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Aurum Biosciences Ltd. Recent Developments
  • 7.2 Hemarina
    • 7.2.1 Hemarina Profile
    • 7.2.2 Hemarina Main Business
    • 7.2.3 Hemarina Artificial Blood Substitute Products, Services and Solutions
    • 7.2.4 Hemarina Artificial Blood Substitute Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Hemarina Recent Developments
  • 7.3 HbO2 Therapeutics
    • 7.3.1 HbO2 Therapeutics Profile
    • 7.3.2 HbO2 Therapeutics Main Business
    • 7.3.3 HbO2 Therapeutics Artificial Blood Substitute Products, Services and Solutions
    • 7.3.4 HbO2 Therapeutics Artificial Blood Substitute Revenue (US$ Million) & (2020-2025)
    • 7.3.5 HbO2 Therapeutics Recent Developments
  • 7.4 KaloCyte Inc.
    • 7.4.1 KaloCyte Inc. Profile
    • 7.4.2 KaloCyte Inc. Main Business
    • 7.4.3 KaloCyte Inc. Artificial Blood Substitute Products, Services and Solutions
    • 7.4.4 KaloCyte Inc. Artificial Blood Substitute Revenue (US$ Million) & (2020-2025)
    • 7.4.5 KaloCyte Inc. Recent Developments
  • 7.5 SpheriTech Ltd.
    • 7.5.1 SpheriTech Ltd. Profile
    • 7.5.2 SpheriTech Ltd. Main Business
    • 7.5.3 SpheriTech Ltd. Artificial Blood Substitute Products, Services and Solutions
    • 7.5.4 SpheriTech Ltd. Artificial Blood Substitute Revenue (US$ Million) & (2020-2025)
    • 7.5.5 SpheriTech Ltd. Recent Developments
  • 7.6 NuvOx Pharma
    • 7.6.1 NuvOx Pharma Profile
    • 7.6.2 NuvOx Pharma Main Business
    • 7.6.3 NuvOx Pharma Artificial Blood Substitute Products, Services and Solutions
    • 7.6.4 NuvOx Pharma Artificial Blood Substitute Revenue (US$ Million) & (2020-2025)
    • 7.6.5 NuvOx Pharma Recent Developments
  • 7.7 Safi Biotherapeutics
    • 7.7.1 Safi Biotherapeutics Profile
    • 7.7.2 Safi Biotherapeutics Main Business
    • 7.7.3 Safi Biotherapeutics Artificial Blood Substitute Products, Services and Solutions
    • 7.7.4 Safi Biotherapeutics Artificial Blood Substitute Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Safi Biotherapeutics Recent Developments

8 Industry Chain Analysis

  • 8.1 Artificial Blood Substitute Industrial Chain
  • 8.2 Artificial Blood Substitute Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Artificial Blood Substitute Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Artificial Blood Substitute Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Artificial Blood Substitute Market Trends
  • Table 2. Artificial Blood Substitute Market Drivers & Opportunity
  • Table 3. Artificial Blood Substitute Market Challenges
  • Table 4. Artificial Blood Substitute Market Restraints
  • Table 5. Global Artificial Blood Substitute Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Artificial Blood Substitute Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Artificial Blood Substitute Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Artificial Blood Substitute Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Artificial Blood Substitute
  • Table 10. Global Artificial Blood Substitute Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Artificial Blood Substitute as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Artificial Blood Substitute Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Artificial Blood Substitute Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Artificial Blood Substitute Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Artificial Blood Substitute Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Artificial Blood Substitute Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Artificial Blood Substitute Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Artificial Blood Substitute Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Artificial Blood Substitute Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Artificial Blood Substitute Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Artificial Blood Substitute Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Artificial Blood Substitute Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Artificial Blood Substitute Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Artificial Blood Substitute Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Artificial Blood Substitute Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Artificial Blood Substitute Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Artificial Blood Substitute Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Artificial Blood Substitute Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Artificial Blood Substitute Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Aurum Biosciences Ltd. Basic Information List
  • Table 32. Aurum Biosciences Ltd. Description and Business Overview
  • Table 33. Aurum Biosciences Ltd. Artificial Blood Substitute Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Artificial Blood Substitute Business of Aurum Biosciences Ltd. (2020-2025)
  • Table 35. Aurum Biosciences Ltd. Recent Developments
  • Table 36. Hemarina Basic Information List
  • Table 37. Hemarina Description and Business Overview
  • Table 38. Hemarina Artificial Blood Substitute Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Artificial Blood Substitute Business of Hemarina (2020-2025)
  • Table 40. Hemarina Recent Developments
  • Table 41. HbO2 Therapeutics Basic Information List
  • Table 42. HbO2 Therapeutics Description and Business Overview
  • Table 43. HbO2 Therapeutics Artificial Blood Substitute Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Artificial Blood Substitute Business of HbO2 Therapeutics (2020-2025)
  • Table 45. HbO2 Therapeutics Recent Developments
  • Table 46. KaloCyte Inc. Basic Information List
  • Table 47. KaloCyte Inc. Description and Business Overview
  • Table 48. KaloCyte Inc. Artificial Blood Substitute Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Artificial Blood Substitute Business of KaloCyte Inc. (2020-2025)
  • Table 50. KaloCyte Inc. Recent Developments
  • Table 51. SpheriTech Ltd. Basic Information List
  • Table 52. SpheriTech Ltd. Description and Business Overview
  • Table 53. SpheriTech Ltd. Artificial Blood Substitute Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Artificial Blood Substitute Business of SpheriTech Ltd. (2020-2025)
  • Table 55. SpheriTech Ltd. Recent Developments
  • Table 56. NuvOx Pharma Basic Information List
  • Table 57. NuvOx Pharma Description and Business Overview
  • Table 58. NuvOx Pharma Artificial Blood Substitute Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Artificial Blood Substitute Business of NuvOx Pharma (2020-2025)
  • Table 60. NuvOx Pharma Recent Developments
  • Table 61. Safi Biotherapeutics Basic Information List
  • Table 62. Safi Biotherapeutics Description and Business Overview
  • Table 63. Safi Biotherapeutics Artificial Blood Substitute Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Artificial Blood Substitute Business of Safi Biotherapeutics (2020-2025)
  • Table 65. Safi Biotherapeutics Recent Developments
  • Table 66. Key Raw Materials Lists
  • Table 67. Raw Materials Key Suppliers Lists
  • Table 68. Artificial Blood Substitute Downstream Customers
  • Table 69. Artificial Blood Substitute Distributors List
  • Table 70. Research Programs/Design for This Report
  • Table 71. Key Data Information from Secondary Sources
  • Table 72. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Artificial Blood Substitute Product Picture
  • Figure 2. Global Artificial Blood Substitute Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Artificial Blood Substitute Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Artificial Blood Substitute Report Years Considered
  • Figure 5. Global Artificial Blood Substitute Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Artificial Blood Substitute Revenue in 2024
  • Figure 7. Artificial Blood Substitute Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Perfluorocarbon-based Oxygen Carrier (PFBOC) Picture
  • Figure 9. Hemoglobin-based Oxygen Carrier (HBOC) Picture
  • Figure 10. Global Artificial Blood Substitute Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Artificial Blood Substitute Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Military
  • Figure 13. Product Picture of Civil
  • Figure 14. Global Artificial Blood Substitute Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Artificial Blood Substitute Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America Artificial Blood Substitute Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific Artificial Blood Substitute Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa Artificial Blood Substitute Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions Artificial Blood Substitute Sales Value (%), (2020-2031)
  • Figure 27. United States Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States Artificial Blood Substitute Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe Artificial Blood Substitute Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China Artificial Blood Substitute Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan Artificial Blood Substitute Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea Artificial Blood Substitute Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia Artificial Blood Substitute Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India Artificial Blood Substitute Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India Artificial Blood Substitute Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India Artificial Blood Substitute Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Artificial Blood Substitute Industrial Chain
  • Figure 49. Artificial Blood Substitute Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed